Bank of America Trims Intrexon (XON) Target Price to $19.00
Intrexon (NYSE:XON) had its price target trimmed by Bank of America from $21.00 to $19.00 in a report released on Friday. The brokerage currently has a neutral rating on the biotechnology company’s stock.
A number of other analysts also recently weighed in on XON. Stifel Nicolaus increased their target price on shares of Intrexon from $39.00 to $57.00 and gave the company a buy rating in a research report on Friday, November 10th. Northland Securities reissued a buy rating and set a $21.00 target price on shares of Intrexon in a research report on Friday, November 10th. ValuEngine downgraded shares of Intrexon from a sell rating to a strong sell rating in a research report on Sunday, December 31st. Finally, Zacks Investment Research raised shares of Intrexon from a sell rating to a hold rating in a research report on Monday, January 22nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. Intrexon presently has a consensus rating of Hold and an average price target of $37.50.
Intrexon (NYSE:XON) opened at $16.09 on Friday. Intrexon has a 52 week low of $10.26 and a 52 week high of $26.99. The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $2,040.00, a P/E ratio of -64.36 and a beta of 1.32.
In other news, CEO Randal J. Kirk bought 1,000,000 shares of the firm’s stock in a transaction on Friday, January 19th. The stock was acquired at an average price of $12.50 per share, with a total value of $12,500,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 55.10% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Third Security LLC boosted its holdings in shares of Intrexon by 2.5% during the 4th quarter. Third Security LLC now owns 57,928,289 shares of the biotechnology company’s stock worth $667,334,000 after buying an additional 1,423,236 shares in the last quarter. Iridian Asset Management LLC CT boosted its holdings in shares of Intrexon by 22.5% during the 4th quarter. Iridian Asset Management LLC CT now owns 4,518,112 shares of the biotechnology company’s stock worth $52,049,000 after buying an additional 828,368 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Intrexon by 5.9% during the 4th quarter. BlackRock Inc. now owns 2,563,111 shares of the biotechnology company’s stock worth $29,528,000 after buying an additional 142,915 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of Intrexon by 41.5% during the 4th quarter. First Trust Advisors LP now owns 2,248,411 shares of the biotechnology company’s stock worth $25,902,000 after buying an additional 659,632 shares in the last quarter. Finally, Peregrine Capital Management LLC boosted its holdings in shares of Intrexon by 10.7% during the 4th quarter. Peregrine Capital Management LLC now owns 645,596 shares of the biotechnology company’s stock worth $7,437,000 after buying an additional 62,268 shares in the last quarter. 74.86% of the stock is owned by institutional investors and hedge funds.
WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/05/bank-of-america-trims-intrexon-xon-target-price-to-19-00.html.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.